Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

Adam S Kittai; Scott Best; Bria Thurlow; Vi Lam; Taylor Hashiguchi; Shaun Goodyear; Daniel O Persky; Craig Okada; Byung Park; Stephen E Spurgeon; Alexey V Danilov

doi:10.3324/haematol.2020.270298

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

Haematologica. 2021 Jul 1;106(7):2022-2025. doi: 10.3324/haematol.2020.270298.

Authors

Affiliations

¹ Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
² University of Arizona Cancer Center, Tucson, AZ.
³ Knight Cancer Institute, Oregon Health and Science University, Portland, OR; City of Hope Comprehensive Cancer Center, Duarte, CA. adanilov@coh.org.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols
B-Lymphocytes
Humans
Indazoles
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Pyrazines

Substances

6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine
Antibodies, Monoclonal, Humanized
Indazoles
Pyrazines
obinutuzumab

Grants and funding

Funding: this Investigator-sponsored study was funded by Gilead Sciences Inc and Roche/Genentech; AVD was supported in part by the Leukemia & Lymphoma Society Scholar in Clinical Research Award #2319-19.